Instrument Inactif

Communiqués Ceapro Inc Toronto S.E.

Actions

CZO

CA1499071076

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Aeterna Zentaris and Ceapro Complete Merger Transaction	03/06	GL
Aeterna Zentaris and Ceapro Complete Merger Transaction	03/06	AQ
Canadian Investment Regulatory Organization Trading Halt - CZO	03/06	AQ
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	29/05	GL
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	29/05	AQ
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	29/04	GL
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	29/04	AQ
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris	28/03	GL
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	12/03	GL
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	12/03	AQ
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	26/02	AQ
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company	26/02	GL
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	23/02	GL
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris	15/02	GL
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro	15/02	AQ
Canadian Investment Regulatory Organization Trade Resumption - CZO	14/12	AQ
Canadian Investment Regulatory Organization Trading Halt - CZO	14/12	AQ
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company	14/12	AQ
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	13/12	GL
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	13/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Ceapro Inc Toronto S.E.

Actions

CZO

CA1499071076

Communiqués

Filtres